Mestastop Solutions

Problem Statement: Most current drugs approved for metastatic cancer, responsible for 90% of deaths, increase survival by a meagre few months. Clinicians need molecules that will delay the tumours' spread and empower them with more time to treat localized cancer. Additionally, the current method of stratifying patients at higher risk of metastasis via the node status often does not work, surprising clinicians. The Solution: Mestastop has identified the gaps as to why anti-metastasis drug discovery failed and has created three proprietary platforms integrating cell biology, genetic engineering, machine learning, animal pharmacology and clinical sampling that do the following:

1. Identifies the rate-limiting steps of metastasis, thereby discovering novel first-in-class targets
2. Screening platform to identify compounds that abrogate the rate-limiting steps
3. Screening platform that identifies the effect of approved drugs on the process of metastasis
4. Predicting the metastatic probability of a treatment-naive primary tumour patient with no second lesion

Mestastop Solutions headquartered in India, Asia, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $17.1M in funding across 24 round(s). With a team of 11-50 employees, Mestastop Solutions is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Mestastop Solutions, raised $541.4K. Discover more about their projects, partnerships, and impact on our platform.